957 The ATR-inhibitor ceralasertib modulates the tumor microenvironment and improves the effect of anti-PDL1 by activating type I IFN pathway

MLA

Dmitry Gabrilovich, et al. “957 The ATR-Inhibitor Ceralasertib Modulates the Tumor Microenvironment and Improves the Effect of Anti-PDL1 by Activating Type I IFN Pathway.” Journal for ImmunoTherapy of Cancer, vol. 11, no. Suppl 1, Nov. 2023. EBSCOhost, https://doi.org/10.1136/jitc-2023-SITC2023.0957.

APA

Dmitry Gabrilovich, Simon Barry, Mark Cobbold, Sehmus Tohumeken, Kathy Mulgrew, Marta Milo, Emilio Sanseviero, Devon Taylor, Mimi Mai, Ali Mostafa, & Serge Fuchs. (2023). 957 The ATR-inhibitor ceralasertib modulates the tumor microenvironment and improves the effect of anti-PDL1 by activating type I IFN pathway. Journal for ImmunoTherapy of Cancer, 11(Suppl 1). https://doi.org/10.1136/jitc-2023-SITC2023.0957

Chicago

Dmitry Gabrilovich, Simon Barry, Mark Cobbold, Sehmus Tohumeken, Kathy Mulgrew, Marta Milo, Emilio Sanseviero, et al. 2023. “957 The ATR-Inhibitor Ceralasertib Modulates the Tumor Microenvironment and Improves the Effect of Anti-PDL1 by Activating Type I IFN Pathway.” Journal for ImmunoTherapy of Cancer 11 (Suppl 1). doi:10.1136/jitc-2023-SITC2023.0957.